Matthew Wongchenko
Overview
Explore the profile of Matthew Wongchenko including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
19
Citations
1809
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
de Bono J, He M, Shi Z, Nowicka M, Bracarda S, Sternberg C, et al.
Eur Urol
. 2025 Jan;
PMID: 39884884
Background And Objective: In the phase 3 IPATential150 trial, ipatasertib addition to abiraterone significantly reduced the risk of disease progression in men with metastatic castration-resistant prostate cancer (mCRPC) with PTEN...
2.
Sweeney C, Petry R, Xu C, Childress M, He J, Fabrizio D, et al.
Clin Cancer Res
. 2024 Jul;
30(18):4115-4122.
PMID: 38990098
Purpose: Enzalutamide after abiraterone progression is commonly used in metastatic castration-resistant prostate cancer despite a low rate of clinical benefit. Analyzing IMbassador250, a phase III trial assessing enzalutamide with or...
3.
Garg M, Couturier D, Nsengimana J, Fonseca N, Wongchenko M, Yan Y, et al.
Nat Commun
. 2022 May;
13(1):2841.
PMID: 35581257
No abstract available.
4.
Garg M, Couturier D, Nsengimana J, Fonseca N, Wongchenko M, Yan Y, et al.
Nat Commun
. 2021 Feb;
12(1):1137.
PMID: 33602918
Adjuvant systemic therapies are now routinely used following resection of stage III melanoma, however accurate prognostic information is needed to better stratify patients. We use differential expression analyses of primary...
5.
Shapiro G, LoRusso P, Cho D, Musib L, Yan Y, Wongchenko M, et al.
Invest New Drugs
. 2020 Aug;
39(1):163-174.
PMID: 32737717
Background: This Phase Ib study explored combination dosing of the allosteric MEK1/2 inhibitor cobimetinib and the ATP-competitive pan-AKT inhibitor ipatasertib. Methods: Patients with advanced solid tumors were enrolled to two...
6.
Ribas A, Daud A, Pavlick A, Gonzalez R, Lewis K, Hamid O, et al.
Clin Cancer Res
. 2019 Nov;
26(1):46-53.
PMID: 31732523
Purpose: To report the 5-year overall survival (OS) landmark and the long-term safety profile of vemurafenib plus cobimetinib (BRAF plus MEK inhibition, respectively) in the BRIM7 study. Patients And Methods:...
7.
Lewis K, Larkin J, Ribas A, Flaherty K, McArthur G, Ascierto P, et al.
Br J Cancer
. 2019 Aug;
121(7):522-528.
PMID: 31417188
Background: This pooled analysis investigated the prognostic value of depth of response in two cohorts of patients with BRAF-mutated metastatic melanoma treated with vemurafenib or cobimetinib plus vemurafenib. Methods: The...
8.
Rydenfelt M, Wongchenko M, Klinger B, Yan Y, Bluthgen N
Life Sci Alliance
. 2019 Jun;
2(4).
PMID: 31253656
Tumors of different molecular subtypes can show strongly deviating responses to drug treatment, making stratification of patients based on molecular markers an important part of cancer therapy. Pharmacogenomic studies have...
9.
Shapiro G, LoRusso P, Kwak E, Pandya S, Rudin C, Kurkjian C, et al.
Invest New Drugs
. 2019 Apr;
38(2):419-432.
PMID: 31020608
Purpose We investigated the combination of the MEK inhibitor, cobimetinib, and the pan-PI3K inhibitor, pictilisib, in an open-label, phase Ib study. Experimental Design Patients with advanced solid tumors were enrolled...
10.
Gide T, Quek C, Menzies A, Tasker A, Shang P, Holst J, et al.
Cancer Cell
. 2019 Feb;
35(2):238-255.e6.
PMID: 30753825
Cancer immunotherapies provide survival benefits in responding patients, but many patients fail to respond. Identifying the biology of treatment response and resistance are a priority to optimize drug selection and...